Effects of Buprenorphine Maintenance Dose on μ-Opioid Receptor Availability, Plasma Concentrations, and Antagonist Blockade in Heroin-Dependent Volunteers
The DOI matches its Crossref record; 43 of the 44 references it cites were found in a registry or an index.
Abstract
The clinical effectiveness of opioid maintenance for heroin dependence is believed to result from a medication's ability to decrease mu-opioid receptor (muOR) availability thereby replacing agonist effects, alleviating withdrawal symptoms and attenuating heroin effects. We empirically tested this hypothesis in five heroin-dependent volunteers who were successively maintained on 32, 16, 2, and 0 mg daily buprenorphine (BUP) tablet doses. We predicted and confirmed that higher BUP doses would decrease in vivo muOR availability (measured with PET and [(11)C]carfentanil), increase plasma levels of BUP and its metabolite nor-BUP, and decrease withdrawal symptoms and hydromorphone (HYD) responses. Relative to placebo, BUP significantly decreased mean (+/-SEM) whole-brain muOR availability 41+/-8, 80+/-2, and 84+/-2% at 2, 16, and 32 mg, respectively. Regions of interest (ROIs) (prefrontal cortex, anterior cingulate, thalamus, amygdala, nucleus accumbens, caudate) showed similar dose-dependent effects. Changes in muOR availability varied across ROIs (prefrontal cortex, 47% vs amygdala, 27%) at BUP 2 mg, but were more homogeneous across ROIs at BUP 32 mg (94-98%; except thalamus, 88%). Relative to placebo (0 ng/ml), peak plasma levels of BUP and nor-BUP were comparable and dose-dependent (0.5-1, 5-6, and 13-14 ng/ml at 2, 16, and 32 mg, respectively). muOR availability decreases were negatively correlated with BUP plasma level and positively correlated with questionnaire-based opioid withdrawal symptoms and attenuation of HYD symptoms. These findings suggest that high-dose BUP maintenance produces near-maximal muOR occupation, muOR availability correlates well with plasma levels, and BUP-related opioid symptoms and antagonist blockade exhibit concentration-effect relationships.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There was a single study by Greenwald et al. 17 (as reported in Greenwald et al. 18 ) that reported occupancy data for mu-opioid occupancy for buprenorphine.”
From Tapering and withdrawing opioids: guidance informed by fundamental principles to minimise withdrawal symptoms (2025) · cites this paper as [17]
In the citing paper
“We derived a curve of best fit for buprenorphine from dose-occupancy data in Greenwald et al. 17 (as reported in Greenwald et al. 18 ) where occupancy was measured 4 h after 12 days of maintenance treatment with doses ranging from 1 to 32 mg (Figure 2 and Table 3).”
From Tapering and withdrawing opioids: guidance informed by fundamental principles to minimise withdrawal symptoms (2025) · cites this paper as [17]
In the citing paper
“This was corroborated by Greenwald et al. (117) who found that higher buprenorphine doses (up to 32 mg given as a tablet*) led to increased plasma buprenorphine levels, decreased μ-opioid receptor availability, and decreased withdrawal symptoms.”
From Craving in Opioid Use Disorder: From Neurobiology to Clinical Practice (2019) · cites this paper as [117]
In the citing paper
“In the same study, heroin craving was found to be significantly correlated with μ-opioid receptor availability and negatively correlated with buprenorphine plasma levels.”
From Craving in Opioid Use Disorder: From Neurobiology to Clinical Practice (2019) · cites this paper as [117]
Citations
Cites
Statistical parametric maps in functional imaging: A general linear approach
Friston, K. J., Holmes, A. P., Worsley, K. J., Poline, J. ‐., Frith, C. D., & Frackowiak, R. S. J. (1994) · Human Brain Mapping · doi:10.1002/hbm.460020402 · Cited by 9,688 · cited 1×
“The global binding potential value was calculated using SPM99 (Friston et al, 1995) as the average value across all brain voxels.”
MethodMcLELLAN, A. T., LUBORSKY, L., WOODY, G. E., & O??BRIEN, C. P. (1980) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-198001000-00006 · Cited by 3,188
Distribution Volume Ratios without Blood Sampling from Graphical Analysis of PET Data
Logan, J., Fowler, J. S., Volkow, N. D., Wang, G.-J., Ding, Y.-S., & Alexoff, D. L. (1996) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-199609000-00008 · Cited by 1,514
New Data from the Addiction Severity Index Reliability and Validity in Three Centers
McLELLAN, A. T., LUBORSKY, L., CACCIOLA, J., GRIFFITH, J., EVANS, F., BARR, H. L., & OʼBRIEN, C. P. (1985) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-198507000-00005 · Cited by 1,503 · cited 1×
“An experienced clinician administered a semistructured interview (SCID-IV; First et al, 1996), and opioid dependence severity was determined using the Addiction Severity Index (McLellan et al, 1985a, b).”
MethodMintun, M. A., Raichle, M. E., Kilbourn, M. R., Wooten, G. F., & Welch, M. J. (1984) · Annals of Neurology · doi:10.1002/ana.410150302 · Cited by 955
Self-citationJasinski, D. R. (1978) · Archives of General Psychiatry · doi:10.1001/archpsyc.1978.01770280111012 · Cited by 782 · cited 1×
“Earlier human laboratory studies showed that administration of subcutaneous BUP (Jasinski et al, 1978; Mello et al, 1982) or sublingual BUP liquid (Bickel et al, 1988; Rosen et al, 1994; Walsh et al, 1995) could attenuate the reinforcing, subjective, and physiological effects of mOR agonists.”
BackgroundA Comparison of Levomethadyl Acetate, Buprenorphine, and Methadone for Opioid Dependence
Johnson, R. E., Chutuape, M. A., Strain, E. C., Walsh, S. L., Stitzer, M. L., & Bigelow, G. E. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011023431802 · Cited by 623 · cited 2×
“Numerous clinical trials support the safety and efficacy of BUP (eg Fudala et al, 1990; Johnson et al, 1995, 2000; Ling et al, 1998), which led to US Food and Drug Administration approval in October 2002 of two sublingual tablet formulations (BUP alone (Subutext) or combined with naloxone using a 4…”
BackgroundMethodAGONIST AND ANTAGONIST PROPERTIES OF BUPRENORPHINE, A NEW ANTINOCICEPTIVE AGENT
COWAN, A., LEWIS, J. W., & MACFARLANE, I. R. (1977) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1977.tb07532.x · Cited by 528
Meyer, C. R., Boes, J. L., Kim, B., Bland, P. H., Zasadny, K. R., Kison, P. V., Koral, K., Frey, K. A., & Wahl, R. L. (1997) · Medical Image Analysis · doi:10.1016/s1361-8415(97)85010-4 · Cited by 460
Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial
Ling, W., Charuvastra, C., Collins, J. F., Batki, S., Brown, L. S., Kintaudi, P., Wesson, D. R., Mcnicholas, L., Tusel, D. J., Malkerneker, U., et al. (1998) · Addiction · doi:10.1046/j.1360-0443.1998.9344753.x · Cited by 402 · cited 2×
“Numerous clinical trials support the safety and efficacy of BUP (eg Fudala et al, 1990; Johnson et al, 1995, 2000; Ling et al, 1998), which led to US Food and Drug Administration approval in October 2002 of two sublingual tablet formulations (BUP alone (Subutext) or combined with naloxone using a 4…”
BackgroundMethod
Research works printed but not linked: 2
- First MB, Spitzer RL, Gibbon M, Williams JBW (1996). Structured Clinical Interview for DSM-IV Axis Disorders—Patient Edition (SCID-I/P, Version 2.0). Biometrics Research Department, NY State Psychiatric Institute: New York.
- Lewis JW, Rance MJ, Sanger DJ (1983). The pharmacology and abuse potential of buprenorphine: a new antagonist analgesic. In: Mello NK (ed). Advances in Substance Abuse Vol. 3 JAI Press: Greenwich, 103–154.
Cited by
Items 301–348 of 348
(2016) · International Journal of Science and Research (IJSR) · doi:10.21275/v5i2.nov161636
(2018) · Elsevier eBooks · doi:10.1016/b978-3-437-23672-3.00006-8
Wolfe, R. C. (2019) · Journal of PeriAnesthesia Nursing · doi:10.1016/j.jopan.2019.05.001
Surgery in the Presence of Active Addiction or Medication Assisted Addiction Treatment
Batta, N., Elkassabany, N. M., & Badiola, I. (2023) · Oxford University Press eBooks · doi:10.1093/med/9780197518519.003.0041
How Does One Approach the Patient With an Opioid Use Disorder?
Ho, J. J., Jones, K. F., Merlin, J. S., & Childers, J. W. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-84702-5.00012-9
Imagerie cérébrale et addictions
Weinstein, A. M., & Potenza, M. N. (2023) · Elsevier eBooks · doi:10.1016/b978-2-294-77934-3.00004-4
Save a Life, Initiate Buprenorphine: Emergency Department Buprenorphine Administration
Kruse, M., & da Silva, J. (2024) · Oxford University Press eBooks · doi:10.1093/med/9780197635513.003.0013
Pain in People with Substance Use Disorder
Hetherington, L., & Farnham, C. (2024) · Oxford University Press eBooks · doi:10.1093/med/9780192864741.003.0004
Perioperative Management of Medications for Substance Use Disorders
Hickey, T. R., & Boyaji, S. (2025) · Oxford University Press eBooks · doi:10.1093/med/9780190902001.003.0006
Response to the letter to the editor
Hickey, T. R., Avila-Quintero, V. J., & Aquino, J. P. D. (2025) · Regional Anesthesia & Pain Medicine · doi:10.1136/rapm-2025-106481
Caritis, S. N., Krans, E. E., & Venkataramanan, R. (2025) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2025.112771
Erdogan, A. R., Karabulut, S., Coşkun, M. N., Tosun, O., Öztaş, F. N. T., Karsavurdan, F., Cinemre, B., Kulaksızoğlu, B., & Metin, Ö. (2025) · Journal of Substance Use · doi:10.1080/14659891.2025.2568066
Pierson, C. J., Khodaparast, N., McWade, M. A., Kuo, Y., Houghton, D. C., Rodriguez, S. L., Korschgen, V. L., Cunningham, K. A., & Wilkes, D. M. (2025) · Trials · doi:10.1186/s13063-025-09171-4
Chapter 10. Psychiatric Comorbidity
Aoun, E. G., & McCance‐Katz, E. F. (2017) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615371709.lg10
Uritsky, T. J., Miskle, B., & Kral, L. A. (2025) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxaf293
Can Buprenorphine Be Combined With Potent Opioids? Synergy, Additive Effects, or Antagonism
Davis, M. P., Caprio, A. J., Strobel, S. D., & O’Connor, M. (2025) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2025.10.028
Ahmed, F., Ng, V., Pan, J., & Hanna, R. B. (2025) · International Anesthesiology Clinics · doi:10.1097/aia.0000000000000500
Pharmacologic and Clinical Considerations of Buprenorphine
Kaye, A. D., Serio, M. A., Dethloff, D. R., Ahmadzadeh, S., Shekoohi, S., & Kaye, A. M. (2025) · Springer eBooks · doi:10.1007/978-3-032-07407-2_14
Use of Potent Opioids for Chronic Pain Management
Freye, E. C. K., & Levy, J. V. (2008) · Springer eBooks · doi:10.1007/978-1-4020-5947-6_4
ヒトゲノム及び遺伝子改変マウスを用いたμオピオイド受容体遺伝子に関する行動および分子薬理学的研究
Ide, S. (2004) · Institutional Repositories DataBase (IRDB) · doi:10.14989/doctor.k10797
Amorim, D. M. G. D. (2014) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Karataş, A. (2011) · Dspace Repository (Marmara Üniversitesi)
For opioid addiction, treatment underdosing can lead to fentanyl overdosing – a physician explains
Grande, L. A. (2025) · The Conversation · doi:10.64628/aai.arap6rgyn
Opioids in clinical practice: From punitive to partnership
Sparkls, E. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-26504-4.00015-6
Pharmacological quest for gold: pursuing safer opioid analgesia
Moss, L. M. (2025) · Leiden Repository (Leiden University)
A Critical Examination of the Mechanism of Action of Buprenorphine: Not Just a Mu Partial Agonist?
Pande, L. J., Nichols, S. D., & Piper, B. J. (2020) · Scholarly Research In Progress · doi:10.64057/001c.154619
Monitoring Protocol for Buprenorphine Treatment for Opioid Use Disorder Patients
Furo, H., & Smith, K. (2024) · Journal of BioMed Research and Reports · doi:10.59657/2837-4681.brs.24.097
Perioperative Management of Patients on Buprenorphine
Vadivelu, N., Mydlo, N., Dextras, C., Ng, J., Silverman, M. L., Kodumudi, G., Chowdhari, S., Hines, R. L., Thomas, D.-A. M., & Hickey, T. R. (2026) · Current Pain and Headache Reports · doi:10.1007/s11916-025-01432-w
Clinical Pharmacist-Led Low-Dose Buprenorphine Initiations (Microinductions): A Case Series
Shiplett, L., Shah, N. K., Field, N., Gruver, S., & Hu, A. (2026) · Journal of Pain & Palliative Care Pharmacotherapy · doi:10.1080/15360288.2026.2624497
Integrative Pain Management in Perioperative Cancer Care
Aboujaoude, A., Kindschuh, W. F., & Mathew, L. (2026) · International Anesthesiology Clinics · doi:10.1097/aia.0000000000000517
Intérêt des antidotes des anesthésiques généraux au bloc opératoire en chirurgie générale.
Khiat, R., & Mihoub, N. (2017) · Dépôt Institutionnel de lUniversité de Tlemcen
Sabol, R. M., Mayrer, B. M., Anderson, T. S., Shuey, B., Roy, P. J., Suda, K. J., & Park, T. W. (2026) · Journal of Substance Use and Addiction Treatment · doi:10.1016/j.josat.2026.209986
Boccuzzi, S., Battal, D., Cowan, D., Dargan, P. I., & Abbate, V. (2026) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000001471
Management of the Critically Ill Patient with Opioid Use Disorder
Imperato, N. S., & Spadaro, A. (2026) · Emergency Medicine Clinics of North America · doi:10.1016/j.emc.2026.04.010
(2026) · Oxford University Press eBooks · doi:10.1093/med/9780198944577.003.0005
Paschke, M., Siddiqui, S. T., Wilson, J., Carroll, G. G., Kroll, M., Ray, B. R., & Winograd, R. (2026) · Journal of the American College of Emergency Physicians Open · doi:10.1016/j.acepjo.2026.100452
Awuku, B., Lai, B., Oberhelman, S. S., & Liu, M. (2026) · Advances in Anesthesia · doi:10.1016/j.aan.2026.06.009
An Individualized, Interdisciplinary Approach to the Perioperative Care of Patients on Buprenorphine
Harin, E., Ashok, V., Andereggen, L., Urman, R. D., & Luedi, M. M. (2026) · Current Pain and Headache Reports · doi:10.1007/s11916-026-01545-w
Total-body [11C]carfentanil PET: Liver-brain axis in methadone vs. buprenorphine treatment
Li, E. J., Wiers, C. E., Hsieh, C., Lee, H., Schmitz, A., Young, A. J., Pond, T., Chang, J., Schubert, E. K., Mach, R. H., et al. (2026) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-026-08144-2
Buprénorphine et gestion de la douleur : mise au point clinique et repères pratiques
Cabé, J., Chappuy, M., Dualé, C., & Bertin, C. (2026) · Therapies · doi:10.1016/j.therap.2026.07.006
Full-text issue: Thai J Pharmacol Vol 27, No 2-3 (2005)
Vol 23, N. 2.-3. (. (2015) · Journal of Basic and Applied Pharmacology
Hakomäki, H. (2023) · UEF eRepo (University of Eastern Finland)
Green, J. L., Dailey-Govoni, T., Vosburg, S. K., Whitley, P., & Passik, S. D. (2026) · Journal of Substance Abuse and Alcoholism · doi:10.47739/substanceabuse.1114
Low-Dose Buprenorphine Initiation Strategies for Pain
Jean, J., & Smith, M. A. (2026) · Annals of Pharmacotherapy · doi:10.1177/10600280261491998
BindingDB Entry 50037434: 18F-labeled sufentanil for PET-imaging of mu-opioid receptors.
BindingDB (2012) · UC San Diego · doi:10.7270/q28916m4
Gu, M., Li, A., Mak, W., Dong, F., Xu, N., Zhang, J., Shi, Y., Zheng, N., Tang, Z., He, Q., et al. (2023) · doi:10.3389/fphar.2023.1089862.s001
Metadata
- Authors
- Greenwald, M. K., Johanson, C.-E., Moody, D. E., Woods, J. H., Kilbourn, M. R., Koeppe, R. A., Schuster, C. R., & Zubieta, J.-K.
- Affiliations
- Wayne State University (US)
- University of Utah (US)
- University of Michigan (US)
- Corresponding author
- Greenwald, Mark K
- Venue
- Neuropsychopharmacology
- Published
- 2003-05-30
- Volume
- 28
- Issue
- 11
- Pages
- 2000-2009
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- OpenAlex
- W2040327352
- Cited by
- 320
- References
- 44
- Citations by year
- 2026: 17 · 2025: 24 · 2024: 16 · 2023: 20 · 2022: 19 · 2021: 23 · 2020: 20 · 2019: 20 · 2018: 11 · 2017: 14 · 2016: 3 · 2015: 12 · 2014: 11 · 2013: 22 · 2012: 14
- FWCI
- 10.50
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Neuropsychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Wayne State University
- U.S. Public Health Service (DA00254)
- National Institute on Drug Abuse (R01 DA 10100, P50DA000254, DA-00254, R01DA010100, P50 DA00254, P01DA000254)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- buprenorphine, heroin addiction, opioid maintenance treatment, dose-response relationship, opioid withdrawal symptoms
- MeSH terms
- Adult, Analysis of Variance, Buprenorphine, Dose-Response Relationship, Drug, Female, Heroin Dependence, Humans, Male, Middle Aged, Narcotic Antagonists, Tomography, Emission-Computed, Receptors, Opioid, mu
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.